Trial
NCT05162027
Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Maryland, Baltimore
Collaborators
Amgen
Condition
Temporomandibular Disorders
Intervention
Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe
Why stopped
Low enrollment rate
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-02